For Newly Diagnosed Men with Prostate Cancer. Welcome to the Club; Here's What You Need to Know.

Trying to outlive my PSA scores with humor, coffee, and the Ghost of a Newfoundland Dog named Oliver

When I first heard the phrase advanced prostate cancer, I imagined something vaguely sinister but undefined, like “advanced calculus” or “advanced interrogation techniques.” It sounded bad, but I didn’t know what it actually meant. Now I do. I’ve learned more about prostates than any reasonable man ever intends to, and the education hasn’t been voluntary.

Let me begin by saying that “advanced” is a misleading word. It sounds like you’ve achieved something, like you’ve moved up a level in a game. In reality, it means the opposite: the cancer has moved up, out, and away, into places it was never invited. “Advanced” simply means it has spread. Usually to the bones. Prostate cancer has a strange fondness for bones. Nobody really knows why, but it behaves like a house guest who keeps sneaking into the good room with the china. If cancer cells are seeds, then bones are the soil they like best. They’re fertile, accommodating, and unfortunately, hard to evict.

So when you hear “advanced,” think metastatic. That’s the real term. It means the disease has gone on a road trip. And when it does, you stop talking about cure and start talking about control, how to keep it on a leash for as long as possible.

The Surprise Guest

There are two ways people discover they have this unwanted visitor. One is the synchronous way: the dramatic, straight-to-the-emergency-room version. A man shows up with back pain or weakness in his legs, and the scans reveal what nobody wanted to see: bright spots in the bones, the tell-tale constellation of metastases. That’s when the word “advanced” makes its unceremonious entrance.

The other way is the asynchronous one. This is the slow, almost bureaucratic version, the one where you’ve already been diagnosed, treated, and declared stable. Then, years later, the numbers start whispering. The PSA rises. The scan shows something suspicious. Suddenly, the disease that was supposed to be sleeping has decided to stretch its legs. It’s the quieter story, but no less unnerving.

Mine was closer to that second one. The long watch, the quiet numbers, the creeping sense that something isn’t quite as dormant as you’d hoped. You get used to measuring time in blood tests. A normal life becomes a series of decimal points.

The PSA Problem

That little acronym (PSA, prostate-specific antigen) has caused more confusion and debate than any three letters deserve. For a while, the experts couldn’t agree whether testing was a blessing or a curse. Too many false alarms, they said. Too many unnecessary biopsies. And they weren’t entirely wrong. But over time, the pendulum has swung back. When used wisely, PSA testing is a decent compass: it doesn’t tell you exactly where you are, but it warns you when you’re drifting off course.

The key is to look at the trend, not the number. A single spike might be noise; a steady climb is a signal. PSA doesn’t diagnose cancer; it hints at it, the way smoke hints at fire. The trick is knowing when to investigate and when to wait. And waiting, by the way, is an underrated skill. Cancer teaches you patience in the most unkind way possible.

The Barnyard of Life

At some point in my reluctant education, I came across what might be the most oddly comforting metaphor in medicine: the barnyard. Imagine, someone once said, that prostate cancers are like animals in a fenced yard.

Some are turtles: slow, harmless creatures who’ll wander around inside the fence forever and never cause trouble. These are the low-grade cancers, the ones you can safely watch while you go about your life.

Then there are the rabbits. They hop around unpredictably. They might stay inside for a while, but one day, and without warning, they’ll find a gap in the fence and make a break for it. Catch a rabbit early, and you can stop it. That’s where PSA testing earns its keep.

And then there are the birds. They’re gone before you even know the gate was open. Aggressive, fast-moving, impossible to contain. No amount of screening will catch them in time. Luckily, there aren’t many birds, but they’re the ones that keep everyone humble.

Most men, it turns out, are housing rabbits. Some have turtles. A few unlucky ones host birds. Knowing which one you’ve got makes all the difference, though sometimes you don’t find out until it’s already flown.

Grades, Not Scores

Once upon a time, cancer severity was reported using something called a Gleason score. It went from 6 to 10, which sounds reassuringly midrange until you realize that 6 was actually the lowest possible number. Telling a man he has a “six out of ten” cancer was, in hindsight, cruelly misleading. It sounded like you were sixty percent dead.

Now they use grade groups, from 1 to 5. Grade group 1 is the harmless turtle. Grade group 5 is the Angry Bird. If you’re in the middle, you’re a rabbit on probation. Mine sits somewhere between those middle markers, annoying but manageable. I’ve learned that these numbers aren’t verdicts; they’re weather forecasts. They tell you what might happen, not what will.

The Bone Attraction

Why bones? That’s the question that nags at everyone. Apparently, the cells in bone marrow and the cancer cells have a kind of unholy chemistry; they stimulate each other, like bad influences at a bar. It’s not that the cancer couldn’t land elsewhere; it just prefers the company of bone cells. It’s a “seed and soil” relationship: the seed is the cancer, the soil is the bone, and once they meet, they tend to thrive. Not the kind of romance anyone hopes for, but nature rarely takes requests.

The Treatment Era

If you’ve ever doubted that science can move fast, look at prostate cancer treatment. Not long ago, there were only two options: surgery if you were lucky, or something called hormone therapy if you weren’t.

The principle behind hormone therapy is brutal in its simplicity: prostate cancer feeds on testosterone, so you cut off the food supply. Starve the beast. It works. Spectacularly, at first. The cancer retreats, PSA levels plummet, and life resumes something like normal. But somewhere in the microscopic shadows, a few cells survive. They adapt. They learn to grow without testosterone. That’s when the term hormone-resistant enters your vocabulary.

And here’s where modern medicine starts to feel a little medieval. Because if you sign up for ADT (androgen deprivation therapy), you soon realize that in the 21st century, we still practice a form of biological torture. To prove your loyalty to science, you must pass through the hands of the hormonal inquisitor. They won’t stretch you on the rack; instead, they chemically unplug your testosterone. You’ll sweat, weep at cat food commercials, and forget why you walked into a room, all in the noble pursuit of evidence-based treatment. It’s effective, yes. But it’s also an experience that would make Torquemada blush.

Ironically, there is a gentler, arguably smarter version of this: estradiol patches or gels.
They suppress testosterone just as effectively as the chemical injections, and in theory, they can even replace some of the benefits of the testosterone you lose, easing hot flashes, preserving bone density, and stabilizing mood. They can make ADT a little less like a tour through the Middle Ages and a little more like modern endocrinology.

So why aren’t estradiol patches standard treatment? Because medicine, like any good bureaucracy, distrusts anything that sounds too easy. Early studies decades ago used high-dose estrogen pills, which caused blood clots, so the entire concept got banished to the “nice idea, maybe later” pile. Never mind that transdermal estradiol (through the skin) avoids that risk almost entirely. It’s the equivalent of banning the electric car because your great-grandfather once caught fire on a horse.

And if hormone therapy is the blunt instrument of the past, radiation has become the precision weapon of the present. It used to be a terrifying word, a synonym for collateral damage. But modern radiation has evolved into something almost elegant: beams so finely targeted they can thread the needle between cure and catastrophe. There’s external beam radiation, where machines map your body like a GPS system and deliver pinpoint destruction; and brachytherapy, the internal version, where radioactive seeds are implanted directly into the prostate.

It’s astonishingly effective, especially when paired with short-term ADT. You might glow metaphorically (and slightly emotionally), but it’s not the blunt-force trauma it once was. The trade-off is usually fatigue, a bladder that sulks for a few months, and the slight possibility of becoming your own nightlight.

Those early hormone therapies have now been joined by a small army of reinforcements:

• Androgen receptor inhibitors, which block the cancer’s ability to even hear testosterone’s signal.

• Chemotherapy, which isn’t as barbaric as it once was, still buys valuable time.

• PARP inhibitors, drugs that exploit flaws in the cancer’s DNA repair system.

• Theranostics, a word that sounds like science fiction but is very real — radioactive molecules that deliver targeted radiation directly to cancer cells, like microscopic drones finding their targets.

Fifteen years ago, the average survival for someone with metastatic prostate cancer was about three years. Now it’s often five, six, sometimes ten. That’s not immortality, but it’s progress. The challenge today isn’t lack of treatment; it’s figuring out the best order to use them in, the best combination, the right moment to pull each lever. In short, the strategy has become more complicated, but the hope is clearer.

Of course, none of this happens in isolation. While you’re learning to navigate the hormonal minefield, your spouse is quietly living through the same campaign but without the medical chart. She watches your moods swing like a metronome, tracks your side effects, and tries to decode which version of you will show up that day: the sentimental philosopher, the exhausted zombie, or the man sweating through his T-shirt while denying it’s a hot flash. It’s not just your cancer anymore; it’s ours. She didn’t sign up for ADT, but she gets the full domestic subscription: no patches, no warnings, just empathy and patience stretched across too many months.

On Progress and Panic

The problem is, progress doesn’t erase uncertainty. It just means you have more time to think about it. Living with prostate cancer is like driving with the “check engine” light permanently on. You can still get to the store, take a vacation, even feel fine, but part of your brain is always listening for the knock in the engine.

I’ve learned to pace my panic. You can’t live in a constant state of DEFCON 1.

So I’ve developed a system:

• DEFCON 5: Coffee and denial. Normal day.

• DEFCON 4: Blood test week. Over-Googling begins.

• DEFCON 3: PSA result pending. Insomnia blossoms.

• DEFCON 2: Small increase detected. Strategic chocolate deployment.

• DEFCON 1: Scan scheduled. Existential dread with a side of sarcasm.

So far, I hover between 4 and 3 most of the time. It’s manageable. It’s living.

Numbers and Prognosis

In this strange new life, you become fluent in numbers: PSA levels, grade groups, months of progression-free survival. But numbers only tell half the story. I’ve met men who live a decade with so-called “bad” cancers, and others whose disease accelerates despite every good sign. The truth is that prostate cancer is less a single disease and more a family of disorders, each with its own temperament.

What seems to matter most, beyond the technicalities, is resilience: the willingness to live with uncertainty. You learn to treat every scan as a weather report, not a prophecy. “Stable” becomes your favourite word. “Progression” becomes the one you dread. And between those two poles, you learn to live, sometimes cautiously, sometimes defiantly, but always aware.

The Agony of Choice (Otherwise Known as “Treatment Selection”)

Nobody tells you that the hardest part of prostate cancer might not be the disease; it’s the menu.

Once diagnosed, you’re handed a list of treatments that sound reassuringly diverse until you realize they all lead to roughly the same statistical outcome: survival, give or take a few side effects and a decent sense of humor.

You get advice, a second opinion, and a third if you can afford it. You read survival curves and success rates. You nod wisely. And then you realize you’re not choosing between cure and death. You’re choosing between types of inconvenience.

Do you want surgery, with a chance of removing the whole gland, and a slightly larger chance of spending the rest of your life getting reacquainted with adult diapers?

Or radiation, which spares you the scalpel but comes with the optional extra of long-term fatigue and a prostate that glows with resentment?

Maybe brachytherapy, the internal radiation approach, where tiny radioactive seeds are planted inside you, turning you into a low-level nuclear device for a few months. Bonus: You can tell airport security you’re literally glowing.

And then there’s ADT (androgen deprivation therapy), the great equalizer. It often joins the party no matter what you choose. So you could have surgery and still end up chemically castrated. Or radiation plus ADT plus hot flashes that could power a small village. In the end, it’s not about which treatment promises the longest life. It’s about which one leaves you most recognizable to yourself. You don’t pick the best option. You pick the one that feels least cruel.

Living With It

Here’s what nobody tells you: you can live a long time with this. You may never be cured, but you can still wake up, make coffee, walk the dog, argue about politics, fix the dishwasher, and curse your cellphone plan. Life goes on. Altered, but recognizably yours. The side effects: hot flashes, fatigue, and emotional whiplash, are part of the new normal. You learn to laugh at them when you can. You learn not to compare. You learn that fear has its own rhythm, and that it quiets when you give it something else to do.

And the science keeps moving. Every year, a new therapy shows up, a little smarter, a little more precise. What was fatal a decade ago is now chronic. What’s chronic today might be curable tomorrow. That’s not blind optimism; it’s the steady march of biology catching up with hope.

What I Know Now

Here’s what I know after living with this for longer than I ever expected:

• Fear is a renewable resource. It never runs out, but it becomes easier to manage.

• Hope isn’t naïve. It’s practical. It gets you out of bed.

• Science works. Slowly, expensively, but relentlessly.

• And above all: Life goes on. Until it doesn’t, but you don’t have to plan for that part yet.

So I live. I test. I watch. I panic occasionally, then I make dinner. Because that’s what survival looks like: not heroism, just persistence with a touch of sarcasm.

I’m still learning from this disease I never asked for. It’s an awful teacher, but the lessons are unforgettable: patience, perspective, and the realization that control is overrated. The trick, I think, is to keep living until panic mode engages. And then, if possible, laugh about it.

Prostate cancer has taught me things I never wanted to know about anatomy, biology, and patience. But it’s also taught me that control is a myth, and endurance is an art. I am not grateful for it, let’s not pretend, but I’m no longer afraid of naming it, living with it, or learning from it. That, for now, is enough.